MORGAN STANLEY has added 875,198 shares of $CDTX to their portfolio, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 06-30-2025 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $CDTX.
CIDARA THERAPEUTICS Hedge Fund Activity
We have seen 78 institutional investors add shares of CIDARA THERAPEUTICS stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. added 2,272,727 shares (+208.0%) to their portfolio in Q2 2025, for an estimated $110,704,532
- POINT72 ASSET MANAGEMENT, L.P. added 1,414,075 shares (+1242.0%) to their portfolio in Q2 2025, for an estimated $68,879,593
- BLACKROCK, INC. added 1,054,772 shares (+1994.0%) to their portfolio in Q2 2025, for an estimated $51,377,944
- MORGAN STANLEY added 875,198 shares (+10651.1%) to their portfolio in Q2 2025, for an estimated $42,630,894
- VESTAL POINT CAPITAL, LP added 504,542 shares (+inf%) to their portfolio in Q1 2025, for an estimated $10,867,834
- SOLEUS CAPITAL MANAGEMENT, L.P. added 462,811 shares (+inf%) to their portfolio in Q2 2025, for an estimated $22,543,523
- VANGUARD GROUP INC added 457,129 shares (+89.7%) to their portfolio in Q2 2025, for an estimated $22,266,753
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CIDARA THERAPEUTICS Insider Trading Activity
CIDARA THERAPEUTICS insiders have traded $CDTX stock on the open market 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CDTX stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA purchased 2,272,727 shares for an estimated $99,999,988
- CHRYSA MINEO has made 2 purchases buying 3,320 shares for an estimated $73,895 and 0 sales.
- LESLIE TARI (CHIEF SCIENTIFIC OFFICER) sold 1,773 shares for an estimated $38,939
- SHANE WARD (COO & CLO) sold 1,664 shares for an estimated $36,542
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
CIDARA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $CDTX in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 08/08/2025
- RBC Capital issued a "Outperform" rating on 06/24/2025
- Guggenheim issued a "Buy" rating on 06/24/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/24/2025
- WBB Securities issued a "Strong Buy" rating on 06/23/2025
- Needham issued a "Buy" rating on 06/23/2025
- Cantor Fitzgerald issued a "Overweight" rating on 06/10/2025
To track analyst ratings and price targets for CIDARA THERAPEUTICS, check out Quiver Quantitative's $CDTX forecast page.
CIDARA THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $CDTX recently. We have seen 10 analysts offer price targets for $CDTX in the last 6 months, with a median target of $59.5.
Here are some recent targets:
- Sara Nik from HC Wainwright & Co. set a target price of $74.0 on 08/08/2025
- Roy Buchanan from JMP Securities set a target price of $66.0 on 08/08/2025
- Joseph Stringer from Needham set a target price of $74.0 on 08/08/2025
- Brian Abrahams from RBC Capital set a target price of $75.0 on 06/24/2025
- Seamus Fernandez from Guggenheim set a target price of $68.0 on 06/24/2025
- Steve Brozak from WBB Securities set a target price of $45.0 on 06/23/2025
- Roy Buchanan from Citizens Capital Markets set a target price of $46.0 on 03/12/2025
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $CDTX ticker page for more data.
